CurrentKaiser PermanentePolicy N/A

Clinical Review Criteria High-Frequency Chest Wall Oscillation Devices (HFCWO)

Clinical review criteria governing medical necessity coverage for HFCWO devices (Vest, ABI/ThAIRapy, Volara, BiWaze) for Kaiser Foundation Health Plan of Washington members, with distinct criteria for Medicare and non-Medicare members and coding/billing guidance.

Policy Summary

PayerKaiser Permanente

PolicyClinical Review Criteria High-Frequency Chest Wall Oscillation Devices (HFCWO)

Policy CodePolicy N/A

Change TypeCriteria updates; coding additions; clarifications

Effective DateDec 13, 2000

Next Review Date

Key ActionWhen requesting HFCWO services, submit the last 6 months of clinical notes from the requesting provider and/or specialist to support medical necessity.

POLICY UPDATE CHANGES

02/04/2025: MPC approved criteria updates for HFCWO devices to better align with current medical evidence.

07/17/2025: Updated coding section to include new HCPCS codes E0469 and A7021 for BiWaze Clear System & Volara system and updated Medicare coverage links and references.

01/19/2016: Defined conditions for neuromuscular disorder.

3Primary device families discussed (Vest, Volara, BiWaze)

2Medicare references (LCD + LCA)

3Main covered indication groups

Coverage Summary

Scope: Clinical review criteria governing medical necessity coverage for High-Frequency Chest Wall Oscillation (HFCWO) devices (vest systems and named devices such as ABI/ThAIRapy, Volara, BiWaze) for Kaiser Foundation Health Plan of Washington members, with distinct criteria for Medicare and non-Medicare members and coding/billing guidance. Subject: High-Frequency Chest Wall Oscillation Devices (HFCWO). Effective date: 2000-12-13; Last review: 2025-07-17.

Coverage stance: mixed — Medicare members: follow applicable LCD/LCA (High Frequency Chest Wall Oscillation Devices L33785 and A52494) for coverage determinations; Non-Medicare members: specified clinical criteria apply and certain devices are considered experimental/not medically necessary. Primary covered indication groups (per policy) are Cystic Fibrosis, Bronchiectasis, and Neuromuscular Disorders with separate pathway criteria (e.g., pulmonologist management and prior CPT/flutter compliance for cystic fibrosis; CT-confirmed bronchiectasis with ≥6 months daily productive cough or frequent exacerbations; neuromuscular disorders with documented failure of standard treatments and rental trial).

Stats / device focus: Primary device families discussed are Vest, Volara, BiWaze (3); policy references Medicare LCD + LCA (2); main covered indication groups listed are Cystic Fibrosis, Bronchiectasis, Neuromuscular Disorders (3). Coding guidance lists covered HCPCS for HFCWO vests (e.g., A7025, A7026, E0480, E0483) and notes that BiWaze and Volara are treated as medically necessary for Medicare when LCD/LCA criteria are met but are non-Medicare: considered experimental / not medically necessary with HCPCS examples A7021, E0469 called out.

Numeric / Temporal Thresholds

Bronchiectasis productive cough durationdaily productive cough for at least 6 continuous months

Hospitalization frequency for neuromuscular pathwaypattern of hospitalizations at least annually or more

Coverage / Medical Necessity Criteria

Non-Medicare Coverage Criteria

Covered when ONE of the following branches is met:

ANY of the following

A. Cystic Fibrosis pathway
- Member has a diagnosis of Cystic Fibrosis
- Member is managed by a pulmonologist
- Has demonstrated compliance with chest physical therapy and flutter device at least twice daily (when age appropriate)
- HFCWO has been recommended by the pulmonologist OR HFCWO considered under this branch

Coding

Covered/Considered Medically Necessary Codes (when criteria met)HCPCSCovered

A7025	High frequency chest wall oscillation system vest; replacement for use with patient-owned equipment, each
A7026	High frequency chest wall oscillation system vest; replacement for use with patient-owned equipment, each (duplicate listing)
E0480	External high-frequency chest wall compression system, each
E0483	High frequency chest wall oscillation system, each

Non-Medicare Not Medically Necessary / Experimental Codes (examples listed)HCPCSNot Covered

A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter)
E0469	High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment

Other codes noted in device listHCPCS

E0480	High frequency chest wall oscillation system vest; included above (listed again in document)
E0483	High frequency chest wall oscillation system

Provider Actions & Authorization

Prior Authorization

Pre-authorization / criteria verification

Verify authorization requirements and applicable coverage by plan type before ordering HFCWO services. For Medicare members, confirm that LCD L33785 and LCA A52494 criteria are met. Use the Pre-authorization Code Check to determine specific prior authorization requirements.

Documentation Required

Submit supporting documentation

When requesting HFCWO services, submit supporting documentation to demonstrate medical necessity. Include the last 6 months of clinical notes from the requesting provider and/or specialist.

Background, Evidence & Definitions

Background: HFCWO is an external, noninvasive airway-clearance modality that uses an inflatable vest connected to an air-pulse generator to deliver rapid compressions/releases (oscillations) to mobilize airway secretions; typical treatment sessions last ~20–30 minutes and operate at frequencies in the ~5–20 Hz range. It is most commonly used in cystic fibrosis and has been explored for bronchiectasis and as adjunctive therapy in neuromuscular disorders with weak cough.

Historical MTAC reviews and evidence limitations: Multiple Kaiser MTAC reviews (2000–2010 and updates through 2010) concluded that evidence on the ABI/ThAIRapy (ThAIRapy/ABI) Vest was insufficient to permit conclusions about effects on health outcomes — randomized trials were small, had design flaws, and did not report key clinical outcomes (e.g., exacerbations, hospitalizations). Later MTAC reviews likewise found little or no empirical evidence supporting HFCWO in neuromuscular disease, citing very limited small trials with short follow-up and threats to internal validity.

Volara and BiWaze evidence limitations: External assessments (Hayes 08/14/2023; ECRI Evidence Analysis revised 01/09/2025) report insufficient published peer-reviewed literature to evaluate the Volara (OLE/Maximus) system’s safety and effectiveness — no studies were identified specifically for Volara/Maximus and predecessor MetaNeb studies were few, small, and at high risk of bias. The policy therefore treats Volara and BiWaze as having inadequate evidence for non-Medicare coverage and lists related HCPCS codes as examples of non-Medicare experimental/not medically necessary items.

Evidence Source	Summary
MTAC conclusions for ABI/ThAIRapy Vest
The scientific evidence does not permit conclusions about the effect of the ThAIRapy/ABI Vest on health outcomes; randomized trials small and inconclusive and did not meet MTAC criteria (see MTAC reviews 2000–2010).
Hayes Technology Assessment (08/14/2023)
Hayes concluded there is not enough published peer‑reviewed literature to evaluate the Volara system (Evidence Analysis Research Brief).
ECRI Evidence Analysis (01/09/2025)
ECRI found no studies examining Volara/Maximus safety and effectiveness; predecessor MetaNeb studies too few and at high risk of bias; additional RCTs needed.

Definitions

HFCWO:

Medicare Determinations (LCD / LCA)

Type	Name	Number
{"text":"LCD","status":""},{"text":"High Frequency Chest Wall Oscillation Devices","status":""},{"text":"L33785","status":""}
{"text":"LCA","status":""},{"text":"High Frequency Chest Wall Oscillation Devices","status":""},{"text":"A52494","status":""}

Revision History

02/04/2025revised

MPC approved criteria updates for HFCWO devices to better align with current medical evidence.

07/17/2025revisedLatest

Updated coding section to include new HCPCS codes E0469 and A7021 for BiWaze Clear System & Volara system and updated Medicare coverage links and references.

01/19/2016clarified

Defined/clarified conditions for neuromuscular disorder and related pathway criteria.